A Study to Evaluate Safety, Tolerability and Pharmacokinetics of MNKD-201 in Patients With Idiopathic Pulmonary Fibrosis
Purpose
MKC-NI-002 is a Phase 1b, randomized, double-blind, placebo-controlled study of nintedanib inhalation powder (MNKD-201) in patients with Idiopathic Pulmonary Fibrosis (IPF). The trial consists of Multiple Ascending Doses (MAD) with the primary objective to evaluate safety, tolerability and pharmacokinetics (PK) of MNKD-201 compared to placebo in patients with IPF.
Condition
- Idiopathic Pulmonary Fibrosis (IPF)
Eligibility
- Eligible Ages
- Between 40 Years and 85 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Is ≥40 to ≤85 years of age at the time of signing the informed consent form. 2. Diagnosis of IPF 3. Either treatment-naive or is currently on background pirfenidone or nerandomilast on a stable dose for at least 3 months prior to Screening. 4. Has FVC >45% of predicted of normal, as determined by the central spirometry reader, during Screening. 5. DLCO corrected for hemoglobin [Visit 1] ≥40% of predicted of normal, within 12 months of Screening. If no historical DLCO is available prior to Screening, this is to be done during Screening and read locally. 6. Has a body weight >40 kg (>88 lbs.) at Screening. 7. For female participants of childbearing potential, agreement to use acceptable birth control 8. For male participants who can father a child and are having intercourse with females of childbearing potential, agreement to use a protocol-recommended method of contraception 9. Is capable of performing spirometry, as required by the study procedures and ATS guidelines. 10. CT chest within 2 years of Screening, consistent with an IPF diagnosis, per investigator assessment.
Exclusion Criteria
- Known explanation for interstitial lung disease, including but not limited to radiation, sarcoidosis, hypersensitivity pneumonitis, and bronchiolitis obliterans organizing pneumonia. 2. Diagnosis of any connective tissue disease, including but not limited to scleroderma/systemic sclerosis, polymyositis/dermatomyositis, systemic lupus erythematosus, and rheumatoid arthritis, regardless of whether or not it is presumed to be related to their pulmonary fibrosis diagnosis. 3. Major extrapulmonary physiological restriction (e.g., chest wall abnormality, large pleural effusion), as determined by the investigator. 4. Significant Cardiovascular diseases 5. Recent systemic infection within 4 weeks before the Screening visit or symptomatic viral or bacterial infection at time of Screening. 6. Prior hospitalization for confirmed coronavirus disease 2019 (COVID-19), acute exacerbation of IPF or any lower respiratory tract infection within 3 months of Screening. 7. Has a history of asthma, with the exception of resolved childhood asthma. 8. Has known obstructive lung disease 9. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin >1.5 times the upper limit of normal (ULN) during Screening. 10. Advanced liver and kidney function. 11. Current or recent (within 30 days of Screening) use of nintedanib. 12. Use of prednisone >10 mg/day within 1 month prior to Screening, or other significant immunosuppression 13. Active lung cancer (primary or metastatic) or any cancer requiring chemotherapy or radiation therapy within 3 years, except appropriately treated non-melanoma skin cancer, localized non-malignant prostate cancer, or in situ carcinoma of uterine cervix. 14. Has participated in another clinical study of a new chemical entity, new device, or a prescription medicine within the 1 month before Screening 15. Current alcohol, medication, or illicit drug abuse 16. Has lost more than 400 mL blood, e.g., as a blood donor, or donor of blood products, during the 3 months prior to Screening. 17. Has received a live vaccine within the 3 months prior to the first dose of study drug. 18. Smokes (any substance including electronic cigarettes and marijuana) within 3 months prior to Screening or is an ex-cigarette smoker who gave up <1 year ago. 19. Has oxygen requirement of > 6 liters/min at rest.
Study Design
- Phase
- Phase 1
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Sequential Assignment
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Cohort 1: MNKD-201 Target Dose or placebo |
Participants will receive a target dose of MNKD-201 (Nintedanib DPI) or placebo, administered via oral inhalation three times daily for 7 days |
|
|
Experimental Cohort 2: MNKD-201 High Dose or placebo |
Participants will receive a high dose of MNKD-201 (Nintedanib DPI) or placebo, administered via oral inhalation twice daily for 7 days |
|
|
Placebo Comparator Placebo |
Participants will receive matching placebo across both cohorts of the study |
|
Recruiting Locations
VALDI
Fresno, California 93720
Fresno, California 93720
Palmtree Clinical Research
Palm Springs, California 92262
Palm Springs, California 92262
New Life Medical Research
Hialeah, Florida 33012
Hialeah, Florida 33012
New Access Research and Medical Services
Miami, Florida 33186
Miami, Florida 33186
Southeastern Research Center
Winston-Salem, North Carolina 27103
Winston-Salem, North Carolina 27103
Low Country Research
Charleston, South Carolina 29406
Charleston, South Carolina 29406
Metroplex Pulmomary & Sleep Center
McKinney, Texas 75069
McKinney, Texas 75069
Pulmonary Medicine Consultants
McKinney, Texas 75071
McKinney, Texas 75071
More Details
- NCT ID
- NCT07344558
- Status
- Recruiting
- Sponsor
- Mannkind Corporation